Federal Register / Vol. 82, No. 189 / Monday, October 2, 2017 / Notices 45873 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Complementary and Integrative Health 

Special Emphasis Panel; NIH Health Care 

Systems Research Collaboratory Review. 

Date: October 31, 2017. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, Bethesda, MD 20892. 

Contact Person: Ashlee Tipton, Ph.D., 

Scientific Review Officer, Division of 

Extramural Activities, National Center for 

Complementary and Integrative Health, 6707 

Democracy Boulevard, Room 401, Bethesda, 

MD 20892, 301–451–3849, ashlee.tipton@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.213, Research and Training 

in Complementary and Integrative Health, 

National Institutes of Health, HHS) 

Dated: September 26, 2017. 

Michelle Trout, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–20987 Filed 9–29–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of HHS-Certified 

Laboratories and Instrumented Initial 

Testing Facilities Which Meet Minimum 

Standards To Engage in Urine Drug 

Testing for Federal Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies federal 

agencies of the laboratories and 

Instrumented Initial Testing Facilities 

(IITF) currently certified to meet the 

standards of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines). 

A notice listing all currently HHScertified laboratories and IITFs is 

published in the Federal Register 

during the first week of each month. If 

any laboratory or IITF certification is 

suspended or revoked, the laboratory or 

IITF will be omitted from subsequent 

lists until such time as it is restored to 

full certification under the Mandatory 

Guidelines. 

If any laboratory or IITF has 

withdrawn from the HHS National 

Laboratory Certification Program (NLCP) 

during the past month, it will be listed 

at the end and will be omitted from the 

monthly listing thereafter. 

This notice is also available on the 

Internet at http://www.samhsa.gov/ 

workplace. 

FOR FURTHER INFORMATION CONTACT: 

Giselle Hersh, Division of Workplace 

Programs, SAMHSA/CSAP, 5600 

Fishers Lane, Room 16N03A, Rockville, 

Maryland 20857; 240–276–2600 (voice). 

SUPPLEMENTARY INFORMATION: The 

Department of Health and Human 

Services (HHS) notifies federal agencies 

of the laboratories and Instrumented 

Initial Testing Facilities (IITF) currently 

certified to meet the standards of the 

Mandatory Guidelines for Federal 

Workplace Drug Testing Programs 

(Mandatory Guidelines). The Mandatory 

Guidelines were first published in the 

Federal Register on April 11, 1988 (53 

FR 11970), and subsequently revised in 

the Federal Register on June 9, 1994 (59 

FR 29908); September 30, 1997 (62 FR 

51118); April 13, 2004 (69 FR 19644); 

November 25, 2008 (73 FR 71858); 

December 10, 2008 (73 FR 75122); April 

30, 2010 (75 FR 22809); and on January 

23, 2017 (82 FR 7920). 

The Mandatory Guidelines were 

initially developed in accordance with 

Executive Order 12564 and section 503 

of Public Law 100–71. The ‘‘Mandatory 

Guidelines for Federal Workplace Drug 

Testing Programs,’’ as amended in the 

revisions listed above, requires strict 

standards that laboratories and IITFs 

must meet in order to conduct drug and 

specimen validity tests on urine 

specimens for federal agencies. 

To become certified, an applicant 

laboratory or IITF must undergo three 

rounds of performance testing plus an 

on-site inspection. To maintain that 

certification, a laboratory or IITF must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories and IITFs in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines. A HHS-certified 

laboratory or IITF must have its letter of 

certification from HHS/SAMHSA 

(formerly: HHS/NIDA), which attests 

that it has met minimum standards. 

In accordance with the Mandatory 

Guidelines dated January 23, 2017 (82 

FR 7920), the following HHS-certified 

laboratories and IITFs meet the 

minimum standards to conduct drug 

and specimen validity tests on urine 

specimens: 

HHS-Certified Instrumented Initial 

Testing Facilities 

Dynacare, 6628 50th Street NW., 

Edmonton, AB Canada T6B 2N7, 780– 

784–1190, (Formerly: GammaDynacare Medical Laboratories). 

HHS-Certified Laboratories 

ACM Medical Laboratory, Inc., 160 

Elmgrove Park, Rochester, NY 14624, 

844–486–9226. 

Alere Toxicology Services, 1111 Newton 

St., Gretna, LA 70053, 504–361–8989/ 

800–433–3823, (Formerly: Kroll 

Laboratory Specialists, Inc., 

Laboratory Specialists, Inc.). 

Alere Toxicology Services, 450 

Southlake Blvd., Richmond, VA 

23236, 804–378–9130, (Formerly: 

Kroll Laboratory Specialists, Inc., 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.). 

Baptist Medical Center-Toxicology 

Laboratory, 11401 I–30, Little Rock, 

AR 72209–7056, 501–202–2783, 

(Formerly: Forensic Toxicology 

Laboratory Baptist Medical Center). 

Clinical Reference Laboratory, Inc., 8433 

Quivira Road, Lenexa, KS 66215– 

2802, 800–445–6917. 

DrugScan, Inc., 200 Precision Road, 

Suite 200, Horsham, PA 19044, 800– 

235–4890. 

Dynacare*, 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4, 519– 

679–1630, (Formerly: GammaDynacare Medical Laboratories). 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655, 662– 

236–2609. 

Laboratory Corporation of America 

Holdings, 7207 N. Gessner Road, 

Houston, TX 77040, 713–856–8288/ 

800–800–2387. 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400/800–437–4986, 

(Formerly: Roche Biomedical 

Laboratories, Inc.). 

Laboratory Corporation of America 

Holdings, 1904 TW Alexander Drive, 

Research Triangle Park, NC 27709, 

919–572–6900/800–833–3984, 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A 

Member of the Roche Group). 

Laboratory Corporation of America 

Holdings, 1120 Main Street, 

Southaven, MS 38671, 866–827–8042/ 

800–233–6339, (Formerly: LabCorp 

Occupational Testing Services, Inc.; 


sradovich on DSK3GMQ082PROD with NOTICES
45874 Federal Register / Vol. 82, No. 189 / Monday, October 2, 2017 / Notices 

MedExpress/National Laboratory 

Center). 

LabOne, Inc. d/b/a Quest Diagnostics, 

10101 Renner Blvd., Lenexa, KS 

66219, 913–888–3927/800–873–8845, 

(Formerly: Quest Diagnostics 

Incorporated; LabOne, Inc.; Center for 

Laboratory Services, a Division of 

LabOne, Inc.). 

MedTox Laboratories, Inc., 402 W. 

County Road D, St. Paul, MN 55112, 

651–636–7466/800–832–3244. 

Legacy Laboratory Services—MetroLab, 

1225 NE 2nd Ave., Portland, OR 

97232, 503–413–5295/800–950–5295. 

Minneapolis Veterans Affairs Medical 

Center, Forensic Toxicology 

Laboratory, 1 Veterans Drive, 

Minneapolis, MN 55417, 612–725– 

2088, Testing for Veterans Affairs 

(VA) Employees Only. 

National Toxicology Laboratories, Inc., 

1100 California Ave., Bakersfield, CA 

93304, 661–322–4250/800–350–3515. 

One Source Toxicology Laboratory, Inc., 

1213 Genoa-Red Bluff, Pasadena, TX 

77504, 888–747–3774, (Formerly: 

University of Texas Medical Branch, 

Clinical Chemistry Division; UTMB 

Pathology-Toxicology Laboratory). 

Pacific Toxicology Laboratories, 9348 

DeSoto Ave., Chatsworth, CA 91311, 

800–328–6942, (Formerly: Centinela 

Hospital Airport Toxicology 

Laboratory). 

Pathology Associates Medical 

Laboratories, 110 West Cliff Dr., 

Spokane, WA 99204, 509–755–8991/ 

800–541–7891x7. 

Phamatech, Inc., 15175 Innovation 

Drive, San Diego, CA 92128, 888– 

635–5840. 

Quest Diagnostics Incorporated, 1777 

Montreal Circle, Tucker, GA 30084, 

800–729–6432, (Formerly: SmithKline 

Beecham Clinical Laboratories; 

SmithKline Bio-Science Laboratories). 

Quest Diagnostics Incorporated, 400 

Egypt Road, Norristown, PA 19403, 

610–631–4600/877–642–2216, 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories). 

Quest Diagnostics Incorporated, 8401 

Fallbrook Ave., West Hills, CA 91304, 

818–737–6370, (Formerly: SmithKline 

Beecham Clinical Laboratories). 

Redwood Toxicology Laboratory, 3700 

Westwind Blvd., Santa Rosa, CA 

95403, 800–255–2159. 

STERLING Reference Laboratories, 2617 

East L Street, Tacoma, Washington 

98421, 800–442–0438. 

US Army Forensic Toxicology Drug 

Testing Laboratory, 2490 Wilson St., 

Fort George G. Meade, MD 20755– 

5235, 301–677–7085, Testing for 

Department of Defense (DoD) 

Employees Only. 

The following laboratory is voluntarily 

withdrawing from the National 

Laboratory Certification Program 

effective September 30, 2017:, 

Aegis Analytical Laboratories, Inc., 345 

Hill Ave., Nashville, TN 37210, 615– 

255–2400, (Formerly: Aegis Sciences 

Corporation, Aegis Analytical 

Laboratories, Inc., Aegis Analytical 

Laboratories). 

* The Standards Council of Canada 

(SCC) voted to end its Laboratory 

Accreditation Program for Substance 

Abuse (LAPSA) effective May 12, 1998. 

Laboratories certified through that 

program were accredited to conduct 

forensic urine drug testing as required 

by U.S. Department of Transportation 

(DOT) regulations. As of that date, the 

certification of those accredited 

Canadian laboratories will continue 

under DOT authority. The responsibility 

for conducting quarterly performance 

testing plus periodic on-site inspections 

of those LAPSA-accredited laboratories 

was transferred to the U.S. HHS, with 

the HHS’ NLCP contractor continuing to 

have an active role in the performance 

testing and laboratory inspection 

processes. Other Canadian laboratories 

wishing to be considered for the NLCP 

may apply directly to the NLCP 

contractor just as U.S. laboratories do., 

Upon finding a Canadian laboratory to 

be qualified, HHS will recommend that 

DOT certify the laboratory (Federal 

Register, July 16, 1996) as meeting the 

minimum standards of the Mandatory 

Guidelines published in the Federal 

Register on January 23, 2017 (82 FR 

7920). After receiving DOT certification, 

the laboratory will be included in the 

monthly list of HHS-certified 

laboratories and participate in the NLCP 

certification maintenance program. 

Charles LoDico, 

Chemist. 

[FR Doc. 2017–21064 Filed 9–29–17; 8:45 am] 

BILLING CODE 4160–20–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Internal Agency Docket No. FEMA–4330– 

DR; Docket ID FEMA–2017–0001] 

Vermont; Amendment No. 1 to Notice 

of a Major Disaster Declaration 

AGENCY: Federal Emergency 

Management Agency, DHS. 

ACTION: Notice. 

SUMMARY: This notice amends the notice 

of a major disaster declaration for the 

State of Vermont (FEMA–4330–DR), 

dated August 16 2017, and related 

determinations. 

DATES: The amendment was issued on 

September 21, 2017. 

FOR FURTHER INFORMATION CONTACT: 

Dean Webster, Office of Response and 

Recovery, Federal Emergency 

Management Agency, 500 C Street SW., 

Washington, DC 20472, (202) 646–2833. 

SUPPLEMENTARY INFORMATION: The 

Federal Emergency Management Agency 

(FEMA) hereby gives notice that 

pursuant to the authority vested in the 

Administrator, under Executive Order 

12148, as amended, James N. Russo, of 

FEMA is appointed to act as the Federal 

Coordinating Officer for this disaster. 

This action terminates the appointment of 

Mark H. Landry as Federal Coordinating 

Officer for this disaster. 

The following Catalog of Federal Domestic 

Assistance Numbers (CFDA) are to be used 

for reporting and drawing funds: 97.030, 

Community Disaster Loans; 97.031, Cora 

Brown Fund; 97.032, Crisis Counseling; 

97.033, Disaster Legal Services; 97.034, 

Disaster Unemployment Assistance (DUA); 

97.046, Fire Management Assistance Grant; 

97.048, Disaster Housing Assistance to 

Individuals and Households In Presidentially 

Declared Disaster Areas; 97.049, 

Presidentially Declared Disaster Assistance— 

Disaster Housing Operations for Individuals 

and Households; 97.050, Presidentially 

Declared Disaster Assistance to Individuals 

and Households—Other Needs; 97.036, 

Disaster Grants—Public Assistance 

(Presidentially Declared Disasters); 97.039, 

Hazard Mitigation Grant. 

Brock Long, 

Administrator, Federal Emergency 

Management Agency. 

[FR Doc. 2017–21118 Filed 9–29–17; 8:45 am] 

BILLING CODE 9111–23–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Internal Agency Docket No. FEMA–3391– 

EM; Docket ID FEMA–2017–0001] 

Puerto Rico; Emergency and Related 

Determinations 

AGENCY: Federal Emergency 

Management Agency, DHS. 

ACTION: Notice. 

SUMMARY: This is a notice of the 

Presidential declaration of an 

emergency for the Commonwealth of 

Puerto Rico (FEMA–3391–EM), dated 

September 18, 2017, and related 

determinations. 

DATES: The declaration was issued 

September 18, 2017. 


sradovich on DSK3GMQ082PROD with NOTICES